Maximizing Opportunity for Therapeutic Success in Cystic Fibrosis Gene Therapy

Strategic Insights -

Investigations into novel gene therapy approaches for cystic fibrosis have highlighted the need to develop treatments for the ultra-rare population with cystic fibrosis who are not candidates for CFTR modulators due to genetic ineligibility or intolerance. Despite the potential of nucleic acid-based therapies (NABTs) to address this unmet need, their clinical development is challenged by small target populations and regulatory complexities. Researchers at Seattle Children's Research Institute are addressing these challenges by exploring the feasibility of sequential participation in NABT trials following previous NABT exposure.

Key Takeaways:

  • Approximately 90% of the population with cystic fibrosis could benefit from CFTR modulators, but a crucial unmet need remains in developing therapies for those who are not candidates for CFTR modulators.
  • The clinical development of NABTs for ultra-rare populations is hindered by small target populations and unique regulatory requirements for long-term safety follow-up.
  • Seattle Children's Research Institute is investigating the potential of sequential participation in NABT trials following previous NABT exposure to maximize therapeutic success for the ultra-rare population with cystic fibrosis.
  • The research highlights the need for proactive planning to facilitate trial opportunities for the population who are not candidates for CFTR modulators.
  • Nicole Mayer-Hamblett and her team at Seattle Children's Research Institute are leading the research effort to develop effective gene therapy treatments for cystic fibrosis.

Statistics:

  • Approximately 90% of the population with cystic fibrosis could benefit from CFTR modulators.
  • The ultra-rare population with cystic fibrosis who are not candidates for CFTR modulators represents a crucial unmet need.
  • The clinical development of NABTs is challenged by small target populations (less than 10% of the total cystic fibrosis population).
  • Recruitment for NABT trials is complex due to long-term safety follow-up requirements and potential short-term and long-term risks associated with genetic therapy cross-exposure or re-exposure.

Sources:

  • NewsRx. Investigators at Seattle Children's Research Institute Report New Data on Gene Therapy (Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials). Respiratory Therapeutics Week. August 18, 2025; p 87.